. Author manuscript; available in PMC: 2015 May 1.

Published in final edited form as: Immunotherapy. 2014 Jul;6(7):833–852. doi: 10.2217/imt.14.51

Table 6.

Combination checkpoint blockade.

Target	Agent	Developmental stage and clinical trial references^†
CTLA4 + PD1	Ipilimumab Nivolumab	Phase I clinical trials 1. NCT01024231 ^† – melanoma Phase I/II clinical trials 1. NCT01928394 ^† – solid tumors 2. NCT02060188 ^† – colon cancer 3. NCT01927419 ^§ – melanoma Phase III clinical trials 1. NCT01844505 ^† – untreated melanoma

CTLA4 + PD1	Ipilimumab Lambrolizumab	Phase I/II clinical trials 1. NCT02089685 ^‡ – melanoma or carcinoma

CTLA4 + PDL1	Tremelimumab+M EDI4736	Phase I clinical trials 1. NCT01975831 ^† – solid tumors 2. NCT02000947 ^† – NSCLC

PD1 + LAG-3	Nivolumab BMS-986016	Phase I clinical trial 1. NCT01968109 ^† – solid tumors

Representative trials, not meant to be exhaustive list of all trials.

Clinical trial status obtained March 2014 from the ClinicalTrials.gov website maintained by the NIH.

^†

Recruiting.

^‡

Not yet recruiting.

^§

Active, not recruiting.

mAb: Monoclonal antibody; NSCLC: Non-small-cell lung cancer.